AU2015231461B2 - Nucleic acid molecule vaccine compositions and uses thereof - Google Patents

Nucleic acid molecule vaccine compositions and uses thereof Download PDF

Info

Publication number
AU2015231461B2
AU2015231461B2 AU2015231461A AU2015231461A AU2015231461B2 AU 2015231461 B2 AU2015231461 B2 AU 2015231461B2 AU 2015231461 A AU2015231461 A AU 2015231461A AU 2015231461 A AU2015231461 A AU 2015231461A AU 2015231461 B2 AU2015231461 B2 AU 2015231461B2
Authority
AU
Australia
Prior art keywords
gly
leu
ser
pro
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015231461A
Other languages
English (en)
Other versions
AU2015231461A1 (en
Inventor
Robert Z. Florkiewicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TAPIMMUNE Inc
Original Assignee
Tapimmune Inc USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tapimmune Inc USA filed Critical Tapimmune Inc USA
Publication of AU2015231461A1 publication Critical patent/AU2015231461A1/en
Application granted granted Critical
Publication of AU2015231461B2 publication Critical patent/AU2015231461B2/en
Priority to AU2021282438A priority Critical patent/AU2021282438A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/50—Vectors comprising a special translation-regulating system utilisation of non-ATG initiation codon
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2015231461A 2014-03-17 2015-03-17 Nucleic acid molecule vaccine compositions and uses thereof Ceased AU2015231461B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021282438A AU2021282438A1 (en) 2014-03-17 2021-12-08 Nucleic acid molecule vaccine compositions and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461954588P 2014-03-17 2014-03-17
US61/954,588 2014-03-17
PCT/US2015/021117 WO2015142963A1 (en) 2014-03-17 2015-03-17 Nucleic acid molecule vaccine compositions and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021282438A Division AU2021282438A1 (en) 2014-03-17 2021-12-08 Nucleic acid molecule vaccine compositions and uses thereof

Publications (2)

Publication Number Publication Date
AU2015231461A1 AU2015231461A1 (en) 2016-10-06
AU2015231461B2 true AU2015231461B2 (en) 2021-09-09

Family

ID=52774612

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015231461A Ceased AU2015231461B2 (en) 2014-03-17 2015-03-17 Nucleic acid molecule vaccine compositions and uses thereof
AU2021282438A Abandoned AU2021282438A1 (en) 2014-03-17 2021-12-08 Nucleic acid molecule vaccine compositions and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021282438A Abandoned AU2021282438A1 (en) 2014-03-17 2021-12-08 Nucleic acid molecule vaccine compositions and uses thereof

Country Status (8)

Country Link
US (8) US9364523B2 (https=)
EP (1) EP3119893A1 (https=)
JP (2) JP2017510297A (https=)
CN (1) CN106459992A (https=)
AU (2) AU2015231461B2 (https=)
BR (1) BR112016021345A8 (https=)
CA (1) CA2942501A1 (https=)
WO (1) WO2015142963A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016184822A1 (en) 2015-05-15 2016-11-24 Curevac Ag Prime-boost regimens involving administration of at least one mrna construct
SMT202200370T1 (it) 2015-11-20 2022-11-18 Memorial Sloan Kettering Cancer Center Composizione per il trattamento del cancro
EP3452082A1 (en) 2016-05-04 2019-03-13 Fred Hutchinson Cancer Research Center Cell-based neoantigen vaccines and uses thereof
US10835596B2 (en) 2016-07-15 2020-11-17 Etubics Corporation Compositions and methods for flavivirus vaccination
JP6903120B2 (ja) * 2016-07-15 2021-07-14 エトゥビクス コーポレーション アルファウイルスワクチン接種のための組成物及び方法
CA3044424C (en) * 2016-11-21 2023-05-23 Nant Holdings Ip, Llc Fractal combination therapy
BR112019015797A2 (pt) 2017-02-01 2020-03-17 Modernatx, Inc. Composições de mrna terapêuticas imunomoduladoras que codificam peptídeos de mutação de oncogene de ativação
CN111065400A (zh) * 2017-10-03 2020-04-24 公益财团法人东京都医学总合研究所 抗流感药物
EP3727468A4 (en) 2017-12-19 2021-09-22 Akouos, Inc. AAV-MEDIATED THERAPEUTIC ANTIBODIES DELIVERY TO THE INTERNAL EAR
CN110117675B (zh) * 2018-02-05 2022-03-04 西比曼生物科技（香港）有限公司 一种实时荧光定量pcr检测rcl的试剂和方法
CN108619499A (zh) * 2018-04-17 2018-10-09 南昌大学 一种结核病疫苗及其制备工艺
CN110144334B (zh) * 2019-05-05 2021-03-16 中国水产科学研究院长江水产研究所 一种共表达草鱼呼肠孤病毒外衣壳蛋白vp4和vp35的重组杆状病毒的制备方法和应用
IL293012A (en) * 2019-11-20 2022-07-01 Bavarian Nordic As Medicinal uses of 4-1bbl modified ankara virus vaccinia ((recombinant mva
BR112022015565A2 (pt) * 2020-02-07 2022-09-27 Modernatx Inc Vacinas de domínio de mrna para sars-cov-2
CN111330002B (zh) * 2020-03-09 2020-12-01 北京鼎成肽源生物技术有限公司 靶向冠状病毒的通用dc细胞疫苗及其制备方法和应用
IL303317A (en) 2020-12-01 2023-07-01 Akouos Inc ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
US6028058A (en) * 1997-07-21 2000-02-22 Ciblex Corporation Methods and compositions for regulating nuclear trafficking of proteins
US6709863B2 (en) 1999-12-08 2004-03-23 Iowa State University Research Foundation Nucleic acid molecules encoding multiple start codons and histidine tags
US20110111413A1 (en) 2001-02-02 2011-05-12 Padgett Hal S Method of optimizing codon usage through dna shuffling
CA2500955A1 (en) 2002-10-03 2004-04-15 Genencor International, Inc. Optimized multi-epitope constructs and uses thereof
CA2685300C (en) 2006-06-01 2017-01-03 Mayo Foundation For Medical Education And Research Immunity to folate receptors
CA2673757A1 (en) 2006-11-30 2008-06-05 Tapimmune Inc. Poxviridae treatment
US20080292918A1 (en) 2007-05-25 2008-11-27 Caine Finnerty Electrochemical system having multiple independent circuits
JP2011502484A (ja) 2007-11-01 2011-01-27 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ Ｈｌａ−ｄｒ結合性ペプチドおよびそれらの使用
US8858952B2 (en) * 2009-02-19 2014-10-14 Mayo Foundation For Medical Education And Research Methods and materials for generating T cells
EP2545071A2 (en) 2010-03-09 2013-01-16 Maksyutov, Amir Polyepitope constructs and methods for their preparation and use
WO2015063647A1 (en) 2013-11-01 2015-05-07 Pfizer Inc. Vectors for expression of prostate-associated antigens

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BONNAL S. et al. "A single internal ribosome entry site containing a G quartet RNA structure drives fibroblast growth factor 2 gene expression at four alternative translation initiation codons" J. Biol. Chem. (2003) 278(41): 39330 - 39336 *

Also Published As

Publication number Publication date
JP2017510297A (ja) 2017-04-13
US20160354455A1 (en) 2016-12-08
CA2942501A1 (en) 2015-09-24
AU2021282438A1 (en) 2021-12-23
JP2019205482A (ja) 2019-12-05
US20160367652A1 (en) 2016-12-22
US20220033844A1 (en) 2022-02-03
US20180163226A1 (en) 2018-06-14
CN106459992A (zh) 2017-02-22
EP3119893A1 (en) 2017-01-25
US10030252B2 (en) 2018-07-24
BR112016021345A2 (https=) 2017-10-03
US20220056473A1 (en) 2022-02-24
US9655956B2 (en) 2017-05-23
AU2015231461A1 (en) 2016-10-06
US20170016026A1 (en) 2017-01-19
US9364523B2 (en) 2016-06-14
BR112016021345A8 (pt) 2022-07-05
US9988643B2 (en) 2018-06-05
US20150258186A1 (en) 2015-09-17
WO2015142963A1 (en) 2015-09-24
US20180230487A1 (en) 2018-08-16

Similar Documents

Publication Publication Date Title
AU2015231461B2 (en) Nucleic acid molecule vaccine compositions and uses thereof
AU2022200016B2 (en) Cancer vaccines and methods of treatment using the same
AU2017336088B2 (en) Tert immunogenic compositions and methods of treatment using the same
CN112930394B (zh) 表达ii类主要组织相容性复合物的癌细胞疫苗和用于产生整合免疫应答的使用方法
EP4045081A1 (en) Cancer vaccine
KR20210041593A (ko) 암의 예방 또는 치료의 방법에 사용하기 위한 암/고환 항원을 암호화하는 바이러스 벡터
KR20220034040A (ko) 신규한 암 항원 및 방법
JP2022539157A (ja) 新規な癌抗原及び方法
KR20210080372A (ko) 신규의 암 항원 및 방법
CA3179694A1 (en) Fusion proteins of ctl antigens for treating melanoma
CN121368491A (zh) 使用重组多肽用于癌症治疗的方法和组合物
CN115667288A (zh) 抗原池
JP2026513981A (ja) 組換えポリペプチドを使用するがん処置のための方法および組成物
HK40019132A (en) Tert immunogenic compositions and methods of treatment using the same

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired